- Home
- XENE vs ZLAB Comparison
XENE vs ZLAB Comparison
Compare XENE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- ZLAB
- Stock Information
- Founded
- XENE 1996
- ZLAB 2013
- Country
- XENE Canada
- ZLAB China
- Employees
- XENE N/A
- ZLAB N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- ZLAB Health Care
- Exchange
- XENE Nasdaq
- ZLAB Nasdaq
- Market Cap
- XENE 2.4B
- ZLAB 3.6B
- IPO Year
- XENE 2014
- ZLAB 2017
- Fundamental
- Price
- XENE $33.18
- ZLAB $36.40
- Analyst Decision
- XENE Strong Buy
- ZLAB Buy
- Analyst Count
- XENE 11
- ZLAB 5
- Target Price
- XENE $54.82
- ZLAB $54.28
- AVG Volume (30 Days)
- XENE 1.5M
- ZLAB 886.5K
- Earning Date
- XENE 08-07-2025
- ZLAB 08-05-2025
- Dividend Yield
- XENE N/A
- ZLAB N/A
- EPS Growth
- XENE N/A
- ZLAB N/A
- EPS
- XENE N/A
- ZLAB N/A
- Revenue
- XENE $7,500,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- XENE N/A
- ZLAB $44.07
- Revenue Next Year
- XENE $253.71
- ZLAB $49.13
- P/E Ratio
- XENE N/A
- ZLAB N/A
- Revenue Growth
- XENE N/A
- ZLAB 43.72
- 52 Week Low
- XENE $26.74
- ZLAB $16.01
- 52 Week High
- XENE $46.00
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- XENE 57.79
- ZLAB 52.67
- Support Level
- XENE $31.09
- ZLAB $34.79
- Resistance Level
- XENE $32.99
- ZLAB $36.73
- Average True Range (ATR)
- XENE 1.21
- ZLAB 1.23
- MACD
- XENE 0.20
- ZLAB -0.46
- Stochastic Oscillator
- XENE 79.20
- ZLAB 25.91
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.